Transarterial chemoembolization combined with lenvatinib and sintilimab <i>vs</i> lenvatinib alone in intermediate-advanced hepatocellular carcinoma
TACE + SL demonstrated superior outcomes in terms of OS and PFS, compared to TACE + L. These findings suggest that the addition of sintilimab might enhance the therapeutic response in patients with intermediate-advanced HCC.
Authors
- Wei-Zhong Zhou (ORCID: https://orcid.org/0000-0001-8013-5607)
- Hai‐Bin Shi (ORCID: https://orcid.org/0000-0003-1293-5789)
- Sheng Liu (ORCID: https://orcid.org/0000-0002-4058-4413)
- Haifeng Zhou (ORCID: https://orcid.org/0000-0003-0968-8182)
- Wei Yang (ORCID: https://orcid.org/0000-0002-7298-5449)
- Bing Wu (ORCID: https://orcid.org/0000-0002-6690-4884)
- Fei-Da Wu
- Di Zhu (ORCID: https://orcid.org/0009-0001-5159-3104)
Institutions
- Nanjing Medical University (CN)
Publication Details
- Journal
- World Journal of Gastrointestinal Oncology
- Published
- 2024-12-11
- DOI
- https://doi.org/10.4251/wjgo.v17.i1.96267
- Citations
- 7
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 2.59